Zealand Pharma reports via Globe News Wire that it dosed its first patient in its Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism (CHI). CHI is a rare pediatric disease with high unmet medical need according to the industry sponsor....
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
